An estimated four out of five Australians with coeliac disease are undiagnosed — we need greater awareness and increased testing
According to criteria published in 1990, which remain the most widely accepted, the diagnosis of coeliac disease is based on typical histological features of the small intestine of an individual on a gluten-containing diet: villous atrophy, crypt hyperplasia and intra-epithelial lymphocytosis.1 Serological tests for coeliac disease, such as for endomysial IgA or transglutaminase IgA, are predictive, but alone are not sufficient for diagnosis. The diagnosis of coeliac disease is confirmed by clinical, serological or histological improvement on a gluten-free diet.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
I am a consultant for Inova Diagnostics (USA), Prometheus Laboratories (USA), and Given Imaging (USA). I hold patents that pertain to the diagnosis, treatment and prevention of coeliac disease, and am the founding director of and a substantial shareholder in Nexpep (Australia). Nexpep is a holding company with shares in ImmusanT (USA), which is developing tests and treatments for coeliac disease. I am a founding shareholder of ImmusanT. My employer, Walter and Eliza Hall Institute of Medical Research (WEHI), has received research funds from Nexpep and Inova Diagnostics. WEHI is a Nexpep shareholder. I am a paid speaker and have developed lecture programs on coeliac disease for AstraZeneca Australia.